Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 18;3(1):e200022.
doi: 10.1148/rycan.2020200022. eCollection 2021 Jan.

Intratumoral Metabolic Heterogeneity and Other Quantitative 18F-FDG PET/CT Parameters for Prognosis Prediction in Esophageal Cancer

Akilan Gopal  1 , Yin Xi  1 , Rathan M Subramaniam  1 , Daniella F Pinho  1
Affiliations

Intratumoral Metabolic Heterogeneity and Other Quantitative 18F-FDG PET/CT Parameters for Prognosis Prediction in Esophageal Cancer

Akilan Gopal et al. Radiol Imaging Cancer. .

Abstract

Purpose: To evaluate the impact of intratumoral metabolic heterogeneity (IMH) and other quantitative fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT parameters for predicting progression-free survival (PFS) and overall survival (OS) in patients with esophageal cancer.

Materials and methods: In this retrospective study, an automated gradient-based segmentation method was used to assess the maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume (MTV), and IMH index of the primary tumor in patients with biopsy-proven adenocarcinoma or squamous cell carcinoma of the esophagus with an initial staging 18F-FDG PET/CT. Data were collected between July 2006 and February 2016. OS and PFS were calculated using multivariable Cox proportional hazards regression with the adjustment (as covariates) of age, sex, weight, stage, tumor type, tumor grade, and treatment. All PET parameters were standardized before analysis. Log-rank tests were performed, and corresponding Kaplan-Meier survival plots were generated.

Results: A total of 71 patients (mean age, 64 years ± 10 [standard deviation], 62:9 men:women) were included. Median follow-up time was 28.2 months (range, 4-38 months), and median survival was 16.1 months (range, 0.1-60.3 months). Higher MTV was associated with reduced PFS for every standard deviation increase (hazard ratio [HR], 0.193; 95% CI: 0.052, 0.711; P = .01). Higher IMH was associated with reduced PFS for every standard deviation decrease in the area under the curve (HR, 10.78; 95% CI: 1.31, 88.96; P = .03).

Conclusion: PFS for patients with esophageal cancer was associated with MTV and with IMH.Keywords: Esophagus, Neoplasms-Primary, PET/CT, Tumor Response © RSNA, 2020.

PubMed Disclaimer

Conflict of interest statement

Disclosures of Conflicts of Interest: A.G. disclosed no relevant relationships. D.F.P. disclosed no relevant relationships. Y.X. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: employed by UT Southwestern Medical Center. Other relationships: disclosed no relevant relationships. R.S. disclosed no relevant relationships.

Figures

Progression-free survival curve based on median cutoff points for area under the curve of cumulative standardized uptake value volume histogram (P = .03). AUC-CSH = area under the curve of a cumulative standardized uptake-volume histogram.
Figure 1:
Progression-free survival curve based on median cutoff points for area under the curve of cumulative standardized uptake value volume histogram (P = .03). AUC-CSH = area under the curve of a cumulative standardized uptake-volume histogram.
A, Axial 18F fluorodeoxyglucose (18F-FDG) PET/CT images in a 55-year-old man with stage III moderately differentiated adenocarcinoma (outlined in purple), with maximum standardized uptake value (SUVmax) of 9.54, metabolic tumor volume (MTV) of 19.12 mL, area under the curve of cumulative standardized uptake value volume histogram (AUC-CSH) of 6458, and a large area under the curve, corresponding to low IMH, B. This patient survived for 91 months after diagnosis. C, Axial 18F-FDG PET/CT images in an 80-year-old man with stage III moderately differentiated adenocarcinoma, with a higher SUVmax of 20.4 and slightly higher MTV of 22.45 mL (compared with the patient in A and B), D, but a lower AUC-CSH of 4805 (significantly smaller area under the curve), corresponding to high IMH. This patient survived for 60 months after diagnosis.
Figure 2:
A, Axial 18F fluorodeoxyglucose (18F-FDG) PET/CT images in a 55-year-old man with stage III moderately differentiated adenocarcinoma (outlined in purple), with maximum standardized uptake value (SUVmax) of 9.54, metabolic tumor volume (MTV) of 19.12 mL, area under the curve of cumulative standardized uptake value volume histogram (AUC-CSH) of 6458, and a large area under the curve, corresponding to low IMH, B. This patient survived for 91 months after diagnosis. C, Axial 18F-FDG PET/CT images in an 80-year-old man with stage III moderately differentiated adenocarcinoma, with a higher SUVmax of 20.4 and slightly higher MTV of 22.45 mL (compared with the patient in A and B), D, but a lower AUC-CSH of 4805 (significantly smaller area under the curve), corresponding to high IMH. This patient survived for 60 months after diagnosis.
See this image and copyright information in PMC

References

    1. Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis Primers 2017;3:17048. - PMC - PubMed
    1. Koshy M, Esiashvilli N, Landry JC, Thomas CR Jr, Matthews RH. Multiple management modalities in esophageal cancer: epidemiology, presentation and progression, work-up, and surgical approaches. Oncologist 2004;9(2):137–146. - PubMed
    1. Dong J, Thrift AP. Alcohol, smoking and risk of oesophago-gastric cancer. Best Pract Res Clin Gastroenterol 2017;31(5):509–517. - PubMed
    1. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95(18):1404–1413. - PubMed
    1. Glenn TF. Esophageal cancer. Facts, figures, and screening. Gastroenterol Nurs 2001;24(6):271–273; quiz 274–275. - PubMed

Substances

LinkOut - more resources